• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SEOM 临床指南：心血管毒性（2018 年）

SEOM clinical guidelines on cardiovascular toxicity (2018).

机构信息

Servicio de Oncología Médica, Complejo Hospitalario Regional Virgen Macarena, Av. Doctor Fedriani, 3, 41009, Seville, Spain.

Servicio de Cardiología, Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigación Biomédica de Salamanca (IBSAL), Ciber CV, Salamanca, Spain.

出版信息

Clin Transl Oncol. 2019 Jan;21(1):94-105. doi: 10.1007/s12094-018-02017-3. Epub 2019 Jan 9.

DOI:10.1007/s12094-018-02017-3
PMID:30627982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6339681/
Abstract

One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor's prognosis. Cardiotoxicity can be related with either a direct side effect of antitumor therapies or an accelerated development of cardiovascular diseases in the presence of preexisting risk factors. Even though it is widely recognized as an alarming clinical problem, scientific evidence is scarce in the management of these complications in cancer patients. Consequently, current recommendations are based on expert consensus. This Guideline represents SEOM's ongoing commitment to progressing and improving supportive care for cancer patients.

摘要

癌症治疗中最常见的副作用之一是心血管疾病，这极大地影响了长期幸存者的预后。心脏毒性可能与抗肿瘤治疗的直接副作用有关，也可能与存在潜在危险因素的情况下加速心血管疾病的发展有关。尽管它被广泛认为是一个令人警惕的临床问题，但在癌症患者中处理这些并发症的科学证据仍然不足。因此，目前的建议是基于专家共识。本指南代表 SEOM 不断致力于为癌症患者提供进展和改善支持性护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/75a524418c25/12094_2018_2017_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/41fe99d84678/12094_2018_2017_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/660bd9bf811f/12094_2018_2017_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/06a3b13869a4/12094_2018_2017_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/7aeb5d077251/12094_2018_2017_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/75a524418c25/12094_2018_2017_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/41fe99d84678/12094_2018_2017_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/660bd9bf811f/12094_2018_2017_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/06a3b13869a4/12094_2018_2017_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/7aeb5d077251/12094_2018_2017_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74da/6339681/75a524418c25/12094_2018_2017_Fig5_HTML.jpg

相似文献

1
SEOM clinical guidelines on cardiovascular toxicity (2018).SEOM 临床指南：心血管毒性（2018 年）
Clin Transl Oncol. 2019 Jan;21(1):94-105. doi: 10.1007/s12094-018-02017-3. Epub 2019 Jan 9.
2
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.加拿大心血管学会癌症治疗相关心血管并发症的评估与管理指南。
Can J Cardiol. 2016 Jul;32(7):831-41. doi: 10.1016/j.cjca.2016.02.078. Epub 2016 Apr 7.
3
Protecting the heart in cancer therapy.在癌症治疗中保护心脏。
F1000Res. 2018 Sep 28;7. doi: 10.12688/f1000research.15190.1. eCollection 2018.
4
Strategies to Prevent Cardiotoxicity.预防心脏毒性的策略。
Curr Treat Options Oncol. 2020 Apr 8;21(4):32. doi: 10.1007/s11864-020-0722-6.
5
Cardiovascular disease in adult survivors of childhood cancer.儿童癌症成年幸存者中的心血管疾病
Annu Rev Med. 2015;66:161-76. doi: 10.1146/annurev-med-070213-054849.
6
Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review.ω-3PUFA 在蒽环类药物诱导的心脏毒性中的保护作用：一项批判性评价。
Int J Mol Sci. 2017 Dec 12;18(12):2689. doi: 10.3390/ijms18122689.
7
Multimodality assessment and treatment of chemotherapy-induced cardiotoxicity.化疗所致心脏毒性的多模态评估与治疗
Future Cardiol. 2015 Jul;11(4):421-4. doi: 10.2217/FCA.15.49. Epub 2015 Aug 4.
8
A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.基于蒽环类药物化疗心脏毒性管理的推荐实用方法：意大利心脏病学会药物心脏毒性与心脏保护工作组意见书
J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1(Suppl 1):e84-e92. doi: 10.2459/JCM.0000000000000381.
9
Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.化疗所致心脏毒性：机制、监测和预防的新见解。
J Cardiovasc Med (Hagerstown). 2018 Jul;19(7):315-323. doi: 10.2459/JCM.0000000000000667.
10
Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.治愈癌症，拯救心脏：心脏肿瘤学不应错过的挑战。
Curr Cardiol Rep. 2016 Jun;18(6):51. doi: 10.1007/s11886-016-0731-z.

引用本文的文献

1
Monitoring high-risk patients for chemotherapy-related cardiotoxicity: A retrospective analysis.监测高危患者的化疗相关心脏毒性：一项回顾性分析。
World J Clin Cases. 2025 Sep 16;13(26):107716. doi: 10.12998/wjcc.v13.i26.107716.
2
Predicting Cardiovascular Risk Factors for Acute Leukemia Patients by Assessing Subclinical Atherosclerosis and Left Ventricular Function Before Chemotherapy.化疗前通过评估亚临床动脉粥样硬化和左心室功能预测急性白血病患者的心血管危险因素
Life (Basel). 2025 Apr 27;15(5):704. doi: 10.3390/life15050704.
3
Risk prediction of heart diseases in patients with breast cancer: A deep learning approach with longitudinal electronic health records data.

本文引用的文献

1
Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient.多模态成像在癌症患者心血管毒性评估中的应用。
JACC Cardiovasc Imaging. 2018 Aug;11(8):1173-1186. doi: 10.1016/j.jcmg.2018.06.003.
2
Radiation-Associated Cardiac Disease: A Practical Approach to Diagnosis and Management.放射性心脏疾病：诊断与管理的实用方法。
JACC Cardiovasc Imaging. 2018 Aug;11(8):1132-1149. doi: 10.1016/j.jcmg.2018.04.028.
3
Cardio-Oncology Services: rationale, organization, and implementation.心血管肿瘤学服务：原理、组织和实施。
乳腺癌患者心脏病风险预测：一种基于纵向电子健康记录数据的深度学习方法。
iScience. 2024 Jun 20;27(7):110329. doi: 10.1016/j.isci.2024.110329. eCollection 2024 Jul 19.
4
Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.乳腺癌幸存者的心力衰竭：关注早期检测和新型生物标志物。
Curr Heart Fail Rep. 2021 Dec;18(6):362-377. doi: 10.1007/s11897-021-00535-w. Epub 2021 Nov 3.
5
Development of a Cardio-Oncology Program in a Community Hospital.社区医院心脏肿瘤项目的开展
JACC CardioOncol. 2019 Dec 17;1(2):310-313. doi: 10.1016/j.jaccao.2019.09.004. eCollection 2019 Dec.
6
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets.氧化应激和炎症：蒽环类药物心脏毒性的决定因素和可能的治疗靶点。
Heart Fail Rev. 2021 Jul;26(4):881-890. doi: 10.1007/s10741-020-10063-9. Epub 2020 Dec 15.
7
Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools.提高癌症治疗中心脏毒性预测：常规循环生物标志物与新型探索性工具的整合。
Arch Toxicol. 2021 Mar;95(3):791-805. doi: 10.1007/s00204-020-02952-7. Epub 2020 Nov 21.
8
Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction.癌症治疗相关心功能障碍的超声心动图实用指南。
J Echocardiogr. 2021 Mar;19(1):1-20. doi: 10.1007/s12574-020-00502-9. Epub 2020 Nov 7.
9
Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?新型抗癌免疫疗法的心血管并发症：新药物引发的旧问题？
Korean Circ J. 2020 Sep;50(9):743-753. doi: 10.4070/kcj.2020.0158. Epub 2020 May 27.
10
Genetic Factors Involved in Cardiomyopathies and in Cancer.心肌病和癌症中的遗传因素。
J Clin Med. 2020 Jun 2;9(6):1702. doi: 10.3390/jcm9061702.
Eur Heart J. 2019 Jun 7;40(22):1756-1763. doi: 10.1093/eurheartj/ehy453.
4
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.免疫治疗毒性的管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266. doi: 10.1093/annonc/mdy162.
5
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗患者的心肌炎。
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.
6
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.2018 年欧洲心脏病学会关于非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中应用的实用指南。
Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
7
Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.癌症治疗相关的 QT 间期延长的发生率、诊断和处理：系统评价。
J Am Heart Assoc. 2017 Dec 7;6(12):e007724. doi: 10.1161/JAHA.117.007724.
8
Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies.癌症治疗引起的心律失常：聚焦于化疗和靶向治疗
Circ Arrhythm Electrophysiol. 2017 Aug;10(8). doi: 10.1161/CIRCEP.117.005443.
9
Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations.临床实践中的心血管肿瘤血液学。立场文件与建议。
Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):474-486. doi: 10.1016/j.rec.2016.12.041. Epub 2017 Mar 18.
10
Emerging Cardiac Imaging Modalities for the Early Detection of Cardiotoxicity Due to Anticancer Therapies.用于早期检测抗癌治疗所致心脏毒性的新兴心脏成像模式
Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):487-495. doi: 10.1016/j.rec.2017.01.004. Epub 2017 Feb 8.